Ocular Delivery: Innovations in Ocular Inserts, Contact Lenses, and Microneedles

Abstract

Ocular drug delivery systems are essential for treating various eye conditions. Ocular conventional drug delivery techniques, such as eye drops (topical administration), often face challenges, like rapid drainage and low bioavailability. To overcome these challenges, scientists have developed ocular inserts with sustained delivery systems. Biocompatible materials, such as hydrogels, polymers, and biodegradable nanoparticles, have been investigated for insert manufacturing. These materials provide controlled release, improved retention time in the outer surface of the eye, and enhanced penetration of active pharmaceutical ingredients passing through the corneal barrier. Innovations in contact lens technology have made it possible to develop drug-loaded lenses that can deliver drugs in a sustained manner directly to the ocular surface by enhancing drug retention time and therapeutic efficacy. Microneedle-based ocular delivery, a relatively new methodology, has made progress by open-hollow and biodegradable microneedles that permit minimally invasive penetration to the sclera or cornea. Microneedle-based ocular delivery provides high bioavailability with prolonged release of drugs. The introduction of smart polymers, nanotechnology, and 3D printing with these systems has enhanced accuracy, patient comfort, and therapeutic efficacy. Together, these advances represent an evolution from current topical ocular treatment options to long-acting, patient-comfort ocular therapies with high efficacy and accuracy.

Keywords

Contact lenses / glaucoma / hydrogels / intravitreal injection / microneedles

References

[1] Patel A, Cholkar K, Agrahari V, Mitra AK. Ocular drug delivery systems: an overview. World J Pharmacol 2013; 2(2): 47-67. [PMID: 25590022 DOI: 10.5497/wjp.v2.i2.47]

[2] Mudgil M, Gupta N, Nagpal M, Pawar P. Nanotechnology: a new approach for ocular drug delivery system. Int J Pharm Pharm Sci 2012; 4(2): 105-12.

[3] Singh M, Bharadwaj S, Lee KE, Kang SG. Therapeutic nanoemulsions in ophthalmic drug administration: concept in formulations and characterization techniques for ocular drug delivery. J Control Release 2020; 328: 895-916. [PMID: 33069743 DOI: 10.1016/j.jconrel.2020.10.025]

[4] Han H, Li S, Xu M, Zhong Y, Fan W, et al. Polymer- and lipid-based nanocarriers for ocular drug delivery: current status and future perspectives. Adv Drug Deliv Rev 2023; 196: 114770. [PMID: 36894134 DOI: 10.1016/j.addr.2023.114770]

[5] Liu LC, Chen YH, Lu DW. Overview of recent advances in nano-based ocular drug delivery. Int J Mol Sci 2023; 24(20): 15352. [PMID: 37895032 DOI: 10.3390/ijms242015352]

[6] Nishida T, Saika S. Cornea and sclera: anatomy and physiology. Cornea 2011; 8: 3-24. [DOI: 10.1016/B978-0-323-06387-6.00008-8]

[7] Assiri AA, Glover K, Mishra D, Waite D, Vora LK, et al. Block copolymer micelles as ocular drug delivery systems. Drug Discov Today 2024; 29(8): 104098. [PMID: 38997002 DOI: 10.1016/j.drudis.2024.104098]

[8] Tsung TH, Tsai YC, Lee HP, Chen YH, Lu DW. Biodegradable polymer-based drug-delivery systems for ocular diseases. Int J Mol Sci 2023; 24(16): 12976. [PMID: 37629157 DOI: 10.3390/ijms241612976]

[9] Gaudana R, Jwala J, Boddu SH, Mitra AK. Recent perspectives in ocular drug delivery. Pharm Res 2009; 26(5): 1197-216. [PMID: 18758924 DOI: 10.1007/s11095-008-9694-0]

[10] Ezike TC, Okpala US, Onoja UL, Nwike CP, Ezeako EC, et al. Advances in drug delivery systems, challenges and future directions. Heliyon 2023; 9(6): e17488. [PMID: 37416680 DOI: 10.1016/j.heliyon.2023.e17488]

[11] Ahmed S, Amin MM, Sayed S. Ocular drug delivery: a comprehensive review. AAPS PharmSciTech 2023; 24(2): 66. [PMID: 36788150 DOI: 10.1208/s12249-023-02516-9]

[12] Raj VK, Mazumder R, Madhra M. Ocular drug delivery system: challenges and approaches. Int J App Pharm 2020; 12(5): 49-57. [DOI: 10.22159/ijap.2020v12i5.38762]

[13] Das S, Saha D, Majumdar S, Giri L. Imaging methods for the assessment of a complex hydrogel as an ocular drug delivery system for glaucoma treatment: opportunities and challenges in preclinical evaluation. Mol Pharm 2022; 19(3): 733-48. [PMID: 35179892 DOI: 10.1021/acs.molpharmaceut.1c00831]

[14] Gote V, Sikder S, Sicotte J, Pal D. Ocular drug delivery: present innovations and future challenges. J Pharmacol Exp Ther 2019; 370(3): 602-24. [PMID: 31072813 DOI: 10.1124/jpet.119.256933]

[15] Pelusi L, Mandatori D, Mastropasqua L, Agnifili L, Allegretti M, et al. Innovation in the development of synthetic and natural ocular drug delivery systems for eye diseases treatment: focusing on drug-loaded ocular inserts, contacts, and intraocular lenses. Pharmaceutics 2023; 15(2): 625. [PMID: 36839947 DOI: 10.3390/pharmaceutics15020625]

[16] Macha S, Hughes PM, Mitra AK. Overview of ocular drug delivery. In: Mitra AK, editor. Ophthalmic drug delivery systems. CRC Press; 2003. pp. 22-33. [DOI: 10.1201/9780203912072]

[17] Irsch K, Guyton DL. Anatomy of eyes. In: Li SZ, Jain A, editors. Encyclopedia of biometrics. Boston, MA: Springer; 2009. pp. 11-16. [DOI: 10.1007/978-0-387-73003-5_253]

[18] Kaplan HJ. Anatomy and function of the eye. Chem Immunol Allergy 2007; 92: 4-10. [PMID: 17264478 DOI: 10.1159/000099236]

[19] Mafee MF, Karimi A, Shah J, Rapoport M, Ansari SA. Anatomy and pathology of the eye: role of MR imaging and CT. Neuroimaging Clin N Am 2005; 15(1): 23-47. [PMID: 15927859 DOI: 10.1016/j.nic.2005.02.005]

[20] Cholkar K, Dasari SR, Pal D, Mitra AK. Eye: anatomy, physiology and barriers to drug delivery. In: Ocular transporters and receptors. Woodhead Publishing; 2013. pp. 1-36. [DOI: 10.1533/9781908818317.1]

[21] Zhu J, Zhang E, Del Rio-Tsonis K . Eye anatomy. Encyclopedia of Life Sciences; 2012. [DOI: 10.1002/9780470015902.a0000108.pub2]

[22] Nishida T, Saika S, Morishige N. Cornea and sclera: anatomy and physiology. In: Mannis MJ, Holland EJ, editors. Cornea: fundamentals, diagnosis and management. 4th ed. New York: Elsevier; 2017. pp. 1-22.

[23] Mulvey F. Eye anatomy, eye movements and vision. In: Gaze interaction and applications of eye tracking: advances in assistive technologies. IGI Global Scientific Publishing; 2012. pp. 10-20. [DOI: 10.4018/978-1-61350-098-9.ch002]

[24] Ansari MW, Nadeem A. Atlas of ocular anatomy. Cham: Springer; 2016. [DOI: 10.1007/978-3-319-42781-2]

[25] Bertelli E. Anatomy of the eye and human visual system. Padua, Italy: Piccin Nuova Libraria S.p.A; 2019.

[26] Boddu SH, Menees AL, Ray A, Mitra AK. A brief overview of ocular anatomy and physiology. In: Mitra AK, editor. Treatise on ocular drug delivery. Bentham Science; 2013. pp. 3-19. [DOI: 10.2174/97816080517551130101]

[27] Hughes MO. Anatomy of the anterior eye for ocularists. J Ophthalmic Prosthet 2004; 8: 25-35.

[28] Leclercq B, Mejlachowicz D, Behar-Cohen F. Ocular barriers and their influence on gene therapy products delivery. Pharmaceutics 2022; 14(5): 998. [PMID: 35631584 DOI: 10.3390/pharmaceutics14050998]

[29] Redzic ZB, Segal MB. The structure of the choroid plexus and the physiology of the choroid plexus epithelium. Adv Drug Deliv Rev 2004; 56(12): 1695-716. [PMID: 15381330 DOI: 10.1016/j.addr.2004.07.005]

[30] Wang L, Zhang H. Ocular barriers as a double-edged sword: preventing and facilitating drug delivery to the retina. Drug Deliv Transl Res 2023; 13(2): 547-67. [PMID: 36129668 DOI: 10.1007/s13346-022-01231-5]

[31] Maulvi FA, Shetty KH, Desai DT, Shah DO, Willcox MDP. Recent advances in ophthalmic preparations: ocular barriers, dosage forms and routes of administration. Int J Pharm 2021; 608: 121105. [PMID: 34537269 DOI: 10.1016/j.ijpharm.2021.121105]

[32] Eghrari AO, Riazuddin SA, Gottsch JD. Overview of the cornea: structure, function, and development. Prog Mol Biol Transl Sci 2015; 134: 7-23. [PMID: 26310146 DOI: 10.1016/bs.pmbts.2015.04.001]

[33] Bernardes R, Dias J, Cunha-Vaz J . Mapping the human blood-retinal barrier function. IEEE Trans Biomed Eng 2004; 52(1): 106-16. [PMID: 15651569 DOI: 10.1109/TBME.2004.839801]

[34] Gote V, Ansong M, Pal D. Prodrugs and nanomicelles to overcome ocular barriers for drug penetration. Expert Opin Drug Metab Toxicol 2020; 16(10): 885-906. [PMID: 32729364 DOI: 10.1080/17425255.2020.1803278]

[35] Gunda S, Hariharan S, Mandava N, Mitra AK. Barriers in ocular drug delivery. In: Tombran-Tink J, Barnstable CJ, editors. Ocular transporters in ophthalmic diseases and drug delivery: ophthalmology research. New Jersey: Humana Totowa; 2008. pp. 399-413. [DOI: 10.1007/s11095-008-9694-0]

[36] Li S, Chen L, Fu Y. Nanotechnology-based ocular drug delivery systems: recent advances and future prospects. J Nanobiotechnol 2023; 21(1): 232. [DOI: 10.1186/s12951-023-01992-2]

[37] Chen MS, Hou PK, Tai TY, Lin BJ. Blood-ocular barriers. Tzu Chi Med J 2008; 20(1): 25-34. [DOI: 10.1016/S1016-3190(08)60004-X]

[38] Freddo TF. A contemporary concept of the blood-aqueous barrier. Progr Retin Eye Res 2013; 32: 181-95. [PMID: 23128417 DOI: 10.1016/j.preteyeres.2012.10.004]

[39] Lee J, Pelis RM. Drug transport by the blood-aqueous humor barrier of the eye. Drug Metab Dispos 2016; 44(10): 1675-81. [PMID: 26895982 DOI: 10.1124/dmd.116.069369]

[40] Coca-Prados M. The blood-aqueous barrier in health and disease. J Glaucoma 2014; 23(suppl 1): S36-8. [DOI: 10.1097/IJG.0000000000000107]

[41] Cunha-Vaz J, Bernardes R, Lobo C . Blood-retinal barrier. Eur J Ophthalmol 2011; 21(suppl 6): 3-9. [PMID: 23264323 DOI: 10.5301/EJO.2010.6049]

[42] Runkle EA, Antonetti DA. The blood-retinal barrier: structure and functional significance. Methods Mol Biol 2011; 686: 133-48. [PMID: 21082369 DOI: 10.1007/978-1-60761-938-3_5]

[43] Wilson S, Ctori I, Shah R, Conway ML, Willis SJ, et al. An investigation of barriers and enablers to community eye care for children in England: a qualitative descriptive study. Ophthalmic Physiol Opt 2023; 43(4): 710-24. [PMID: 36881493 DOI: 10.1111/opo.13109]

[44] Raviola G. The structural basis of the blood-ocular barriers. Exp Eye Res 1977; 25(suppl): 27-63. [DOI: 10.1016/S0014-4835(77)80009-2]

[45] Patel PB, Shastri D, Shelat P, Shukla A. Ophthalmic drug delivery system: challenges and approaches. Syst Rev Pharm 2010; 1(2): 113. [DOI: 10.4103/0975-8453.75042]

[46] del Amo EM. Topical ophthalmic administration: can a drug instilled onto the ocular surface exert an effect at the back of the eye? Front Drug Deliv 2022; 2: 954771. [DOI: 10.3389/fddev.2022.954771]

[47] Jenita JJ, Rathore SS, Manjula D, Barnabas W . Packaging, container, and closure of ophthalmic products. In: Mehra NK, editor. Complex ophthalmic dosage forms: advances in biomedical applications and future perspectives. Singapore: Springer Nature Singapore; 2025. pp. 355-392. [DOI: 10.1007/978-981-96-6306-4_12]

[48] Tsung TH, Chen YH, Lu DW. Updates on biodegradable formulations for ocular drug delivery. Pharmaceutics 2023; 15(3): 734. [PMID: 36986595 DOI: 10.3390/pharmaceutics15030734]

[49] Kalantzis GK, Verity DH, Rose GE. Periocular implantation cysts: a late complication of ophthalmic surgery. Eye 2014; 28(8): 1004-7. [PMID: 24924444 DOI: 10.1038/eye.2014.111]

[50] Yetgin C, Demiröz FNT, Takka T. Ocular drug delivery routes: diseases overview and advanced administration methods. Fabad J Pharm Sci 2024; 49(3): 627-46. [DOI: 10.55262/fabadeczacilik.1496246]

[51] Bisht R, Mandal A, Jaiswal JK, Rupenthal ID. Nanocarrier mediated retinal drug delivery: overcoming ocular barriers to treat posterior eye diseases. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2018; 10(2): e1473. [PMID: 28425224 DOI: 10.1002/wnan.1473]

[52] Thang NH, Chien TB, Cuong DX. Polymer-based hydrogels applied in drug delivery: an overview. Gels 2023; 9(7): 523. [PMID: 37504402 DOI: 10.3390/gels9070523]

[53] Viswanadhan Vasantha P, Sherafudeen SP, Rahamathulla M, Mathew ST, Murali S, Alshehri S, et al. Combination of cellulose derivatives and chitosan-based polymers to investigate the effect of permeation enhancers added to in situ nasal gels for the controlled release of loratadine and chlorpheniramine. Polymers 2023; 15(5): 1206. [DOI: 10.3390/polym15051206]

[54] Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev 2013; 65(1): 36-48. [PMID: 23036225 DOI: 10.1016/j.addr.2012.09.037]

[55] Taskar P, Tatke A, Majumdar S. Advances in the use of prodrugs for drug delivery to the eye. Expert Opin Drug Deliv 2017; 14(1): 49-63. [PMID: 27441817 DOI: 10.1080/17425247.2016.1208649]

[56] Mahlumba P, Choonara YE, Kumar P, Du Toit LC, Pillay V. Stimuli-responsive polymeric systems for controlled protein and peptide delivery: future implications for ocular delivery. Molecules 2016; 21(8): 1002. [PMID: 27483234 DOI: 10.3390/molecules21081002]

[57] Kuno N, Fujii S. Recent advances in ocular drug delivery systems. Polymers 2011; 3(1): 193-221. [DOI: 10.3390/polym3010193]

[58] Devhadrao NV, Siddhaia M. Review on ocular insert drug delivery system. J Drug Deliv Ther 2018; 8(5-S): 115-21. [DOI: 10.22270/jddt.v8i5-s.1991]

[59] Sahane NK, Banarjee SK, Gaikwad DD, Jadhav SL, Throat RM. Ocular inserts: a review. Drug Invent Today 2010; 2(1): 57-64.

[60] Turaeva A, Bakhrushina E, Zhalyalova D, Korochkina T, Stepanova O, et al. Ocular inserets as a modern therapy trend in opthalmopathology. Int J App Pharm 2023; 15(6): 45-52. [DOI: 10.22159/ijap.2023v15i6.49037]

[61] Kumar BP, Harish G, Bhowmik D. Ocular inserts: a novel controlled drug delivery system. Pharma Innovation 2013; 1(12): 16. [DOI: 10.4018/978-1-61350-353-9.ch001]

[62] Farkas E, Abboud H, Nagy N, Hofmeister B, Ostorházi E, et al. Formulation and development of nanofiber-based ophthalmic insert for the treatment of bacterial conjunctivitis. Int J Mol Sci 2024; 25(17): 9228. [PMID: 39273175 DOI: 10.3390/ijms25179228]

[63] Bertens CJF, Martino C, van Osch MC, Lataster A, Dias AJAA, et al. Design of the ocular coil, a new device for non-invasive drug delivery. Eur J Pharm Biopharm 2020; 150: 120-30. [DOI: 10.1016/j.ejpb.2020.03.010]

[64] Yu W, Wu Z. Ocular delivery of CRISPR/Cas genome editing components for treatment of eye diseases. Adv Drug Deliv Rev 2021; 168: 181-95. [PMID: 32603815 DOI: 10.1016/j.addr.2020.06.011]

[65] Gade SK, Nirmal J, Garg P, Venuganti VVK. Corneal delivery of moxifloxacin and dexamethasone combination using drug-eluting mucoadhesive contact lens to treat ocular infections. Int J Pharm 2020; 591: 120023. [PMID: 33127488 DOI: 10.1016/j.ijpharm.2020.120023]

[66] García-Estrada P, García-Bon MA, López-Naranjo EJ, Basaldúa-Pérez DN, Santos A, et al. Polymeric implants for the treatment of intraocular eye diseases: trends in biodegradable and non-biodegradable materials. Pharmaceutics 2021; 13(5): 701. [PMID: 34065798 DOI: 10.3390/pharmaceutics13050701]

[67] Pereira ICF, van Mechelen RJS, Wyss HM, Pinchuk L, Beckers HJM, et al. Magnetically actuated glaucoma drainage device for regulating intraocular pressure after implantation. Microsyst Nanoeng 2023; 9(1): 92. [PMID: 37484503 DOI: 10.1038/s41378-023-00561-9]

[68] Rykowska I, Nowak I, Nowak R. Soft contact lenses as drug delivery systems: a review. Molecules 2021; 26(18): 5577. [PMID: 34577045 DOI: 10.3390/molecules26185577]

[69] Morrison PW, Khutoryanskiy VV. Advances in ophthalmic drug delivery. Ther Deliv 2014; 5(12): 1297-315. [PMID: 25531930 DOI: 10.4155/tde.14.75]

[70] Franco P, De Marco I. Contact lenses as ophthalmic drug delivery systems: a review. Polymers (Basel) 2021; 13(7): 1102. [PMID: 33808363 DOI: 10.3390/polym13071102]

[71] Choi SW, Kim J. Therapeutic contact lenses with polymeric vehicles for ocular drug delivery: a review. Materials (Basel) 2018; 11(7): 1125. [PMID: 29966397 DOI: 10.3390/ma11071125]

[72] Hynes A. The promise of drug-eluting contact lenses. Mod Optom 2024: 11-3. Available from: https://modernod.com/topics/contact-lenses/the-promise-of-drug-eluting-contact-lenses/38780/.

[73] Ciolino JB, Hoare TR, Iwata NG, Behlau I, Dohlman CH, et al. A drug-eluting contact lens. Invest Ophthalmol Vis Sci 2009; 50(7): 3346-52. [PMID: 19136709 DOI: 10.1167/iovs.08-2826]

[74] Charman WN. Developments in the correction of presbyopia I: spectacle and contact lenses. Ophthalmic Physiol Opt 2014; 34(1): 8-29. [PMID: 24205890 DOI: 10.1111/opo.12091]

[75] van der Worp E, Bornman D, Ferreira DL, Faria-Ribeiro M, Garcia-Porta N, et al. Modern scleral contact lenses: a review. Cont Lens Anterior Eye 2014; 37(4): P240-50. [DOI: 10.1016/j.clae.2014.02.002]

[76] Sart S, Ma T, Li Y. Preconditioning stem cells for in vivo delivery. Biores Open Access 2014; 3(4): 137-49. [PMID: 25126478 DOI: 10.1089/biores.2014.0012]

[77] Gillespie RL, Lloyd IC, Black GC. The use of autozygosity mapping and next-generation sequencing in understanding anterior segment defects caused by an abnormal development of the lens. Hum Hered 2014; 77(1-4): 118-37. [PMID: 25060275 DOI: 10.1159/000362599]

[78] Bengani LC, Hsu KH, Gause S, Chauhan A. Contact lenses as a platform for ocular drug delivery. Expert Opin Drug Deliv 2013; 10(11): 1483-96. [PMID: 23875917 DOI: 10.1517/17425247.2013.821462]

[79] Alvarez-Lorenzo C, Hiratani H, Gómez-Amoza JL, Martínez-Pacheco R, Souto C, et al. Soft contact lenses capable of sustained delivery of timolol. J Pharm Sci 2002; 91(10): 2182-92. [PMID: 12226845 DOI: 10.1002/jps.10209]

[80] Pearson RM. A review of the limitations of the first hydrogel contact lenses. Clin Exp Optom 2010; 93(1): 15-25. [PMID: 19961507 DOI: 10.1111/j.1444-0938.2009.00444.x]

[81] Topete A, Pinto CA, Barroso H, Saraiva JA, Barahona I, et al. High hydrostatic pressure as sterilization method for drug-loaded intraocular lenses. ACS Biomater Sci Eng 2020; 6(7): 4051-61. [DOI: 10.1021/acsbiomaterials.0c00412]

[82] Gulsen D, Chauhan A. Ophthalmic drug delivery through contact lenses. Invest Ophthalmol Vis Sci 2004; 45(7): 2342- 7. [PMID: 15223815 DOI: 10.1167/iovs.03-0959]

[83] White CJ, Byrne ME. Molecularly imprinted therapeutic contact lenses. Expert Opin Drug Deliv 2010; 7(6): 765-80. [PMID: 20408742 DOI: 10.1517/17425241003770098]

[84] Kim J, Peng CC, Chauhan A. Extended release of dexamethasone from silicone-hydrogel contact lenses containing vitamin E. J Control Release 2010; 148(1): 110-6. [PMID: 20691228 DOI: 10.1016/j.jconrel.2010.07.119]

[85] Bose P. Next-gen contact lenses: beyond vision correction. News Medical; 2024. Available from: https://www.news-medical.net/health/Next-Gen-Contact-Lenses-Beyond-Vision-Correction.aspx.

[86] Haworth K, Travis D, Leslie L, Fuller D, Pucker AD. Silicone hydrogel versus hydrogel soft contact lenses for differences in patient-reported eye comfort and safety. Cochrane Database Syst Rev 2023; 9(9): CD014791. [PMID: 37724689 DOI: 10.1002/14651858.CD014791.pub2]

[87] Ishihara K, Shi X, Fukazawa K, Yamaoka T, Yao G, et al. Biomimetic-engineered silicone hydrogel contact lens materials. ACS Appl Bio Mater 2023; 6(9): 3600-16. [PMID: 37616500 DOI: 10.1021/acsabm.3c00296]

[88] Said O. Advancing multifocal contact lens design with biometry. Optom Times J 2024; 16(1). Available from: https://www.optometrytimes.com/view/advancing-multifocal-contact-lens-design-with-biometry.

[89] Mertz L. Smart contact lenses keep an eye on health. IEEE Pulse 2023; 14(3): 20-3. [DOI: 10.1109/MPULS.2023.3294087]

[90] Kazanskiy NL, Khonina SN, Butt MA. Smart contact lenses-a step towards non-invasive continuous eye health monitoring. Biosensors (Basel) 2023; 13(10): 933. [PMID: 37887126 DOI: 10.3390/bios13100933]

[91] Rueff E. Stability is an important quality in toric lenses. Optom Times J 2024; 16(7). Available from: https://www.optometrytimes.com/view/stability-is-an-important-quality-in-toric-lenses.

[92] Sakr A, Kamal A, Jacob L, Homsi R, Butt H. Comprehensive review on the synthesis, properties and applications of nanocomposite contact lenses. Polym Rev 2024; 65(1): 1-46. [DOI: 10.1080/15583724.2024.2400961]

[93] Glover K, Mishra D, Gade S, Vora LK, Wu Y, et al. Microneedles for advanced ocular drug delivery. Adv Drug Deliv Rev 2023; 201: 115082. [PMID: 37678648 DOI: 10.1016/j.addr.2023.115082]

[94] Thakur Singh RR, Tekko I, McAvoy K, McMillan H, Jones D, et al. Minimally invasive microneedles for ocular drug delivery. Expert Opin Drug Deliv 2017; 14(4): 525-37. [PMID: 27485251 DOI: 10.1080/17425247.2016.1218460]

[95] Thakur RR, Tekko IA, Al-Shammari F, Ali AA, McCarthy H, et al. Rapidly dissolving polymeric microneedles for minimally invasive intraocular drug delivery. Drug Deliv Transl Res 2016; 6(6): 800-15. [PMID: 27709355 DOI: 10.1007/s13346-016-0332-9]

[96] Rojekar S, Parit S, Gholap AD, Manchare A, Nangare SN, et al. Revolutionizing eye care: exploring the potential of microneedle drug delivery. Pharmaceutics 2024; 16(11): 1398. [PMID: 39598522 DOI: 10.3390/pharmaceutics16111398]

[97] Gadzinski P, Froelich A, Wojtylko M, Bialek A, Krysztofiak J, et al. Microneedle-based ocular drug delivery systems - recent advances and challenges. Beilstein J Nanotechnol 2022; 13(1): 1167-84. [PMID: 36348935 DOI: 10.3762/bjnano.13.98]

[98] Prausnitz MR. Microneedles for transdermal drug delivery. Adv Drug Deliv Rev 2004; 56(5): 581-7. [PMID: 15019747 DOI: 10.1016/j.addr.2003.10.023]

[99] Gupta P, Yadav KS. Applications of microneedles in delivering drugs for various ocular diseases. Life Sci 2019; 237: 116907. [PMID: 31606378 DOI: 10.1016/j.lfs.2019.116907]

[100] Patel SR, Lin AS, Edelhauser HF, Prausnitz MR. Suprachoroidal drug delivery to the back of the eye using hollow microneedles. Pharm Res 2011; 28(1): 166-76. [PMID: 20857178 DOI: 10.1007/s11095-010-0271-y]

[101] Gade S, Glover K, Mishra D, Sharma S, Guy O, et al. Hollow microneedles for ocular drug delivery. J Control Release 2024; 371: 43-66. [PMID: 38735395 DOI: 10.1016/j.jconrel.2024.05.013]

[102] Bao Q, Zhang X, Hao Z, Li Q, Wu F, et al. Advances in polysaccharide-based microneedle systems for the treatment of ocular diseases. Nanomicro Lett 2024; 16(1): 268. [PMID: 39136800 DOI: 10.1007/s40820-024-01477-3]

[103] Day R. Polysaccharides in ocular tissue. Am J Ophthalmol 1950; 33(2): 224-6. [PMID: 15405339 DOI: 10.1016/0002-9394(50)90840-3]

[104] Dou S, Wang Q, Zhang B, Wei C, Wang H, et al. Single-cell atlas of keratoconus corneas revealed aberrant transcriptional signatures and implicated mechanical stretch as a trigger for keratoconus pathogenesis. Cell Discov 2022; 8(1): 66. [PMID: 35821117 DOI: 10.1038/s41421-022-00397-z]

[105] Kim JW, Zhang P, Gehlbach P, Iordachita I, Kobilarov M. Micromanipulation in surgery: autonomous needle insertion inside the eye for targeted drug delivery. Arxiv preprint arxiv:2306.17421. 2023. [DOI: 10.48550/arXiv.2306.17421]

[106] Jiménez-Gómez Y, Alba-Molina D, Blanco-Blanco M, Pérez-Fajardo L, Reyes-Ortega F, et al. Novel treatments for age-related macular degeneration: a review of clinical advances in sustained drug delivery systems. Pharmaceutics 2022; 14(7): 1473. [PMID: 35890368 DOI: 10.3390/pharmaceutics14071473]

[107] Wu Y, Vora LK, Donnelly RF, Singh TRR. Rapidly dissolving bilayer microneedles enabling minimally invasive and efficient protein delivery to the posterior segment of the eye. Drug Deliv Transl Res 2023; 13(8): 2142-58. [PMID: 35713782 DOI: 10.1007/s13346-022-01190-x]

[108] Giri BR, Jakka D, Sandoval MA, Kulkarni VR, Bao Q. Advancements in ocular therapy: a review of emerging drug delivery approaches and pharmaceutical technologies. Pharmaceutics 2024; 16(10): 1325. [PMID: 39458654 DOI: 10.3390/pharmaceutics16101325]

[109] Arribada RG, Rodrigues-Braz D, Silva-Cunha A, Behar-Cohen F. Excipients in drug delivery systems: a comprehensive review of approved inactive ingredients for human ophthalmic formulations. Eur J Pharm Biopharm 2025; 208: 114637. [PMID: 39837427 DOI: 10.1016/j.ejpb.2025.114637]

[110] Zaki M, Pardo J, Carracedo G. A review of international medical device regulations: contact lenses and lens care solutions. Cont Lens Anterior Eye 2019; 42(2): 136-46. [PMID: 30446241 DOI: 10.1016/j.clae.2018.11.001]

[111] Olowe M, Parupelli SK, Desai S. A review of 3d-printing of microneedles. Pharmaceutics 2022; 14(12): 2693. [PMID: 36559187 DOI: 10.3390/pharmaceutics14122693]

[112] Alotaibi TA, Iyire A, Assaf S, Dahmash EZ. Development and characterization of niosomes loaded mucoadhesive biodegradable ocular inserts for extended release of pilocarpine HCL. Futur J Pharm Sci 2024; 10(1): 22. [DOI: 10.1186/s43094-024-00598-1]

[113] Anumolu SS, Singh Y, Gao D, Stein S, Sinko PJ. Design and evaluation of novel fast forming pilocarpine-loaded ocular hydrogels for sustained pharmacological response. J Control Release 2009; 137(2): 152-9. [PMID: 19341773 DOI: 10.1016/j.jconrel.2009.03.016]

[114] Rathore KS, Nema RK, Sisodia SS. Timolol maleate a gold standard drug in glaucoma used as ocular films and inserts: an overview. Int J Pharm Sci Rev Res 2010; 3(1): 23-9.

[115] Lee A, Blair HA. Dexamethasone intracanalicular insert: a review in treating post-surgical ocular pain and inflammation. Drugs 2020; 80(11): 1101-8. [PMID: 32588339 DOI: 10.1007/s40265-020-01344-6]

[116] Campochiaro PA, Hafiz G, Shah SM, Bloom S, Brown DM, et al. Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert. Ophthalmology 2010; 117(7): 1393-9. [PMID: 20202684 DOI: 10.1016/j.ophtha.2009.11.024]

[117] Ara T, Sharma S, Bhat SA, Bhandari A, Deva AS, et al. Preparation and evaluation of ocular inserts of diclofenac sodium for controlled drug delivery. Der Pharm Lett 2014; 6(6): 93-9.

[118] Keny S, Sawaikar L. Sustained release of ciprofloxacin hydrochloride and loteprednol etabonate from ophthalmic ocuserts for treatment of bacterial conjunctivitis. Indian J Pharm Sci 2024; 86(3): 1-9. [DOI: 10.36468/pharmaceutical-sciences.1353]

[119] Mirzaeei S, Alizadeh M. Design and evaluation of soluble ocular insert for controlled release of chloramphenicol. J Rep Pharm Sci 2017; 6(2): 123-33. [DOI: 10.4103/2322-1232.222620]

[120] Alzahrani A, Youssef AAA, Nyavanandi D, Tripathi S, Bandari S, et al. Design and optimization of ciprofloxacin hydrochloride biodegradable 3D printed ocular inserts: full factorial design and in-vitro and ex-vivo evaluations: part II. Int J Pharm 2023; 631: 122533. [PMID: 36566827 DOI: 10.1016/j.ijpharm.2022.122533]

[121] Aburahma MH, Mahmoud AA. Biodegradable ocular inserts for sustained delivery of brimonidine tartarate: preparation and in vitro/in vivo evaluation. AAPS PharmSciTech 2011; 12(4): 1335-47. [PMID: 21979886 DOI: 10.1208/s12249-011-9701-3]

[122] Shadambikar G, Marathe S, Patil A, Joshi R, Bandari S, et al. Novel application of hot melt extrusion technology for preparation and evaluation of valacyclovir hydrochloride ocular inserts. AAPS PharmSciTech 2021; 22(1): 1-7. [PMID: 33447869 DOI: 10.1208/s12249-020-01916-5]

[123] Karnik I, Youssef AA, Joshi P, Munnangi SR, Narala S, et al. Formulation development and characterization of dual drug loaded hot-melt extruded inserts for better ocular therapeutic outcomes: sulfacetamide/prednisolone. J Drug Deliv Sci Technol 2023; 84: 104558. [DOI: 10.1016/j.jddst.2023.104558]

[124] Jethava JK, Jethava GK. Design, formulation, and evaluation of novel sustain release bioadhesive in-situ gelling ocular inserts of ketorolac tromethamine. Int J Pharm Investig 2014; 4(4): 226. [PMID: 25426444 DOI: 10.4103/2230-973X.143131]

[125] Koradia K, Dedakia A, Koradia H. Development and in vitro-in vivo evaluation of ocular insert containing ketorolac tromethamine and moxifloxacin hydrochloride. Ann Pharm Fr 2025; 83(1): 163-172. [PMID: 39413968 DOI: 10.1016/j.pharma.2024.10.002]

[126] Duman G, Yildir I, Macit M, Genç E, Sümer E, et al. Development and evaluation of 3D-printed ocular insert containing liposomal moxifloxacin. J Drug Deliv Sci Technol 2024; 92: 105353. [DOI: 10.1016/j.jddst.2024.105353]

[127] Pandey P, Panwar AS, Dwivedi P, Jain P, Agrawal A, et al. Design and evaluation of ocular inserts for controlled drug delivery of acyclovir. Int J Pharm Biol Arch 2011; 2(4): 1106-10.

[128] Hady MA, El-Zahaby SA. Phospholipid free nano-vesicles of brinzolamide biopolymer ocular insert; design, in vitro and in vivo evaluation. J Pharm Sci 2024; 113(8): 2178-87. [PMID: 38428457 DOI: 10.1016/j.xphs.2024.02.021]

[129] Rubião F, Araújo ACF, Sancio JB, Nogueira BS, Franca JR, et al. Topical bimatoprost insert for primary open-angle glaucoma and ocular hypertension treatment-a phase II controlled study. Curr Drug Deliv 2021; 18(7): 1022-6. [PMID: 33388018 DOI: 10.2174/1567201818666210101112256]

[130] Dayoub RA, Laham A. Preparation and in-vitro evaluation of timolol maleate loaded ocular inserts by using various polymers. Res J Pharm Technol 2023; 16(3): 1259-66. [DOI: 10.52711/0974-360x.2023.00208]

[131] Terreni E, Chetoni P, Burgalassi S, Tampucci S, Zucchetti E, et al. A hybrid ocular delivery system of cyclosporine-a comprising nanomicelle-laden polymeric inserts with improved efficacy and tolerability. Biomater Sci 2021; 9(24): 8235-48. [DOI: 10.1039/d1bm01453f]

[132] Terreni E, Burgalassi S, Chetoni P, Tampucci S, Zucchetti E, et al. Development and characterization of a novel peptide-loaded antimicrobial ocular insert. Biomolecules 2020; 10(5): 664. [PMID: 32344824 DOI: 10.3390/biom10050664]

[133] Harikumar SL, Balasubramaniam J, Kumar MT, Pandit J. In vitro characterization of physically reinforced ocular inserts of indomethacin. Acta Pharma Sci 2004; 46(1).

[134] Franca JR, Foureaux G, Fuscaldi LL, Ribeiro TG, Castilho RO, et al. Chitosan/hydroxyethyl cellulose inserts for sustained-release of dorzolamide for glaucoma treatment: in vitro and in vivo evaluation. Int J Pharm 2019; 570: 118662. [PMID: 31491481 DOI: 10.1016/j.ijpharm.2019.118662]

[135] Saettone MF, Torracca MT, Pagano A, Giannaccini B, Rodriguez L, et al. Controlled release of pilocarpine from coated polymeric ophthalmic inserts prepared by extrusion. Int J Pharm 1992; 86(2-3): 159-66. [DOI: 10.1016/0378-5173(92)90193-6]

[136] Taghe S, Mirzaeei S, Alany RG, Nokhodchi A. Polymeric inserts containing Eudragit^® l100 nanoparticle for improved ocular delivery of azithromycin. Biomedicines 2020; 8(11): 466. [PMID: 33142768 DOI: 10.3390/biomedicines8110466]

[137] Rao MV, Shyale S. Preparation and evaluation of ocular inserts containing norfloxacin. Turk J Med Sci 2004; 34(4): 239-46.

[138] Amar A, Ashish K, Ajaykumar P, Anand J . Formulation and evalution of controlled release ocular inserts of betaxolol hydrochloride. IOSR J Pharm 2012; 2(5): 34-8. [DOI: 10.9790/3013-25203438]

[139] Omer S, Zelkó R. A systematic review of drug-loaded electrospun nanofiber-based ophthalmic inserts. Pharmaceutics 2021; 13(10): 1637. [PMID: 34683930 DOI: 10.3390/pharmaceutics13101637]

[140] Mirzaeei S, Barfar D. Design and development of antibacterial/anti-inflammatory dual drug-loaded nanofibrous inserts for ophthalmic sustained delivery of gentamicin and methylprednisolone: in vitro bioassay, solvent, and method effects’ evaluation. Adv Pharm Bull 2022; 12(3): 531-40. [PMID: 35935049 DOI: 10.34172/apb.2022.056]

[141] Km M, Kulkarni GT. Design, development and evaluation of controlled release levobunolol hydrochloride ocular inserts for glaucoma therapy. J Chronother Drug Deliv 2012; 3: 87-97.

[142] Souto EB, Dias-Ferreira J, López-Machado A, Ettcheto M, Cano A, et al. Advanced formulation approaches for ocular drug delivery: state-of-the-art and recent patents. Pharmaceutics 2019; 11(9): 460. [PMID: 31500106 DOI: 10.3390/pharmaceutics11090460]

[143] Mostafa M, Al Fatease A, Alany RG, Abdelkader H . Recent advances of ocular drug delivery systems: prominence of ocular implants for chronic eye diseases. Pharmaceutics 2023; 15(6): 1746. [PMID: 37376194 DOI: 10.3390/pharmaceutics15061746]

[144] https://patents.google.com/.

[145] Elliott W, Chan J. Etafilcon a drug-eluting contact lens with ketotifen (acuvue theravision with ketotifen). Intern Med Alert 2022; 44(10).

[146] Novack GD, Barnett M. Ocular drug delivery systems using contact lenses. J Ocul Pharmacol Ther 2020; 36(8): 595-601. [DOI: 10.1089/jop.2020.0024]

[147] Kompella UB, Kadam RS, Lee VH. Recent advances in ophthalmic drug delivery. Ther Deliv 2010; 1(3): 435-56. [PMID: 21399724 DOI: 10.4155/TDE.10.40]

[148] Gruber E. The state of contact lenses in the United States in the 1990s. Int Contact Lens Clin 1991; 18(9-10): P175-7. [DOI: 10.1016/0892-8967(91)90003-I]

[149] Maulvi FA, Patil RJ, Desai AR, Shukla MR, Vaidya RJ, et al. Effect of gold nanoparticles on timolol uptake and its release kinetics from contact lenses: in vitro and in vivo evaluation. Acta Biomater 2019; 86: 350-62. [PMID: 30625414 DOI: 10.1016/j.actbio.2019.01.004]

[150] Yañez F, Martikainen L, Braga ME, Alvarez-Lorenzo C, Concheiro A, et al. Supercritical fluid-assisted preparation of imprinted contact lenses for drug delivery. Acta Biomater 2011; 7(3): 1019-30. [PMID: 20934541 DOI: 10.1016/j.actbio.2010.10.003]

[151] Bin Sahadan MY, Tong WY, Tan WN, Leong CR, Bin Misri MN, et al. Phomopsidione nanoparticles coated contact lenses reduce microbial keratitis causing pathogens. Exp Eye Res 2019; 178: 10-4. [PMID: 30243569 DOI: 10.1016/j.exer.2018.09.011]

[152] Tripathi S, Yadav KS. Development of brimonidine niosomes laden contact lenses for extended release and promising delivery system in glaucoma treatment. Daru 2024; 32(1): 161-75. [PMID: 38158475 DOI: 10.1007/s40199-023-00500-z]

[153] Daull P, Garrigue JS, Liang H, Baudouin C. Use of a cationic emulsion of latanoprost to treat glaucoma patients with ocular surface disease: a preclinical review. J Ocul Pharmacol Ther 2023; 39(4): 240-51. [PMID: 37015075 DOI: 10.1089/jop.2022.0155]

[154] Michałkiewicz O, Nowak I, Nowak R, Rykowska I. Daily disposable contact lenses as a platform for ocular drug delivery of cyclosporine A. Physicochem Probl Miner Process 2023; 59(4): 172794. [DOI: 10.37190/ppmp/172794]

[155] Vivero-Lopez M, Muras A, Silva D, Serro AP, Otero A, et al. Resveratrol-loaded hydrogel contact lenses with antioxidant and antibiofilm performance. Pharmaceutics 2021; 13(4): 532. [PMID: 33920327 DOI: 10.3390/pharmaceutics13040532]

[156] Salz JJ, Reader AL 3rd, Schwartz LJ, Van Le K. Treatment of corneal abrasions with soft contact lenses and topical diclofenac. J Refract Surg 1994; 10(6): 640- 6. [PMID: 7719534 DOI: 10.3928/1081-597X-19941101-09]

[157] Ucar F, Kadioglu E. Effectiveness of ketorolac-soaked bandage contact lens for pain management after photorefractive keratectomy. Cutan Ocul Toxicol 2023; 42(2): 55-60. [PMID: 37042853 DOI: 10.1080/15569527.2023.2201832]

[158] Karlgard CC, Jones LW, Moresoli C. Ciprofloxacin interaction with silicon-based and conventional hydrogel contact lenses. Eye Contact Lens 2003; 29(2): 83-9. [PMID: 12695709 DOI: 10.1097/01.ICL.0000061756.66151.1C]

[159] Hyatt AJ, Rajan MS, Burling K, Ellington MJ, Tassoni A, et al. Release of vancomycin and gentamicin from a contact lens versus a fibrin coating applied to a contact lens. Invest Ophthalmol Vis Sci 2012; 53(4): 1946-52. [PMID: 22408014 DOI: 10.1167/iovs.11-8607]

[160] Morgan SR, Pilia N, Hewitt M, Moses RL, Moseley R, et al. Controlled in vitro delivery of voriconazole and diclofenac to the cornea using contact lenses for the treatment of Acanthamoeba keratitis. Int J Pharm 2020; 579: 119102. [PMID: 32007592 DOI: 10.1016/j.ijpharm.2020.119102]

[161] Dave SB, Toma HS, Kim SJ . Changes in ocular flora in eyes exposed to ophthalmic antibiotics. Ophthalmology 2013; 120(5): 937-41. [PMID: 23415422 DOI: 10.1016/j.ophtha.2012.11.005]

[162] Ruben M, Watkins R . Pilocarpine dispensation for the soft hydrophilic contact lens. Br J Ophthalmol 1975; 59(8): 455- 8. [PMID: 1203231 DOI: 10.1136/bjo.59.8.455]

[163] Xu B, Liu T. Travoprost loaded microemulsion soaked contact lenses: improved drug uptake, release kinetics and physical properties. J Drug Deliv Sci Technol 2020; 57: 101792. [DOI: 10.1016/j.jddst.2020.101792]

[164] Yan F, Liu Y, Han S, Zhao Q, Liu N. Retracted article: bimatoprost imprinted silicone contact lens to treat glaucoma. AAPS PharmSciTech 2020; 21(2): 63. [PMID: 31933030 DOI: 10.1208/s12249-020-1622-6]

[165] Malaekeh-Nikouei B, Vahabzadeh SA, Mohajeri SA. Preparation of a molecularly imprinted soft contact lens as a new ocular drug delivery system for dorzolamide. Curr Drug Deliv 2013; 10(3): 279-85. [PMID: 23360228 DOI: 10.2174/1567201811310030004]

[166] C De Guzman LM, De Guzman GQ, Borromeo EC. Brinzolamide-loaded soft contact lens for ophthalmic delivery. Ther Deliv 2022; 13(4): 233-47. [PMID: 35615865 DOI: 10.4155/tde-2022-0005]

[167] Razeghinejad MR, Sawchyn AK, Katz LJ. Fixed combinations of dorzolamide-timolol and brimonidine-timolol in the management of glaucoma. Expert Opin Pharmacother 2010; 11(6): 959-68. [PMID: 20307220 DOI: 10.1517/14656561003667540]

[168] Centofanti M, Oddone F, Gandolfi S, Hommer A, Boehm A, et al. Comparison of travoprost and bimatoprost plus timolol fixed combinations in open-angle glaucoma patients previously treated with latanoprost plus timolol fixed combination. Am J Ophthalmol 2010; 150(4): 575-80. [PMID: 20688314 DOI: 10.1016/j.ajo.2010.05.003]

[169] Strohmaier K, Snyder E, DuBiner H, Adamsons I ; the Dorzolamide-Timolol Study Group. The efficacy and safety of the dorzolamide-timolol combination versus the concomitant administration of its components. Ophthalmology 1998; 105(10): 1936-44. [PMID: 9787367 DOI: 10.1016/s0161-6420(98)91045-4]

[170] Jiang J, Gill HS, Ghate D, McCarey BE, Patel SR, et al. Coated microneedles for drug delivery to the eye. Invest Ophthalmol Vis Sci 2007; 48(9): 4038-43. [PMID: 17724185 DOI: 10.1167/iovs.07-0066]

[171] Amer M, Chen RK. Hydrogel-forming microneedle arrays for sustained and controlled ocular drug delivery. J Eng Sci Med Diagn Ther 2020; 3(4): 041003. [DOI: 10.1115/1.4048481]

[172] Jiang J, Moore JS, Edelhauser HF, Prausnitz MR. Intrascieral drug delivery to the eye using hollow microneedles. Pharm Res 2009; 26(2): 395-403. [PMID: 18979189 DOI: 10.1007/s11095-008-9756-3]

[173] Mahadevan G, Sheardown H, Selvaganapathy P. PDMS embedded microneedles as a controlled release system for the eye. J Biomater Appl 2013; 28(1): 20-7. [PMID: 22262574 DOI: 10.1177/0885328211433778]

[174] Edelhauser HF, Verhoeven RS, Burke B, Struble CB, Patel SR. Intraocular distribution and targeting of triamcinolone acetonide suspension administered into the suprachoroidal space. Invest Ophthalmol Vis Sci 2014; 55(13): 5259.

[175] Chiang B, Kim YC, Edelhauser HF, Prausnitz MR. Circumferential flow of particles in the suprachoroidal space is impeded by the posterior ciliary arteries. Exp Eye Res 2016; 145: 424-31. [PMID: 26976663 DOI: 10.1016/j.exer.2016.03.008]

[176] Hosoya K-I, Tachikawa M. The inner blood-retinal barrier: molecular structure and transport biology. In: Cheng CY, editor. Biology and regulation of blood-tissue barriers. Advances in experimental medicine and biology, Vol 763. New York, NY: Springer; 2013. pp. 85-104. [DOI: 10.1007/978-1-4614-4711-5_4]

[177] Gu B, Liu J, Li X, Ma Q, Shen M, et al. Real-time monitoring of suprachoroidal space (SCS) following SCS injection using ultra-high resolution optical coherence tomography in guinea pig eyes. Invest Ophthalmol Vis Sci 2015; 56(6): 3623-34. [PMID: 26047049 DOI: 10.1167/iovs.15-16597]

[178] Chiang B, Kim YC, Doty AC, Grossniklaus HE, Schwendeman SP, et al. Sustained reduction of intraocular pressure by supraciliary delivery of brimonidine-loaded poly(lactic acid) microspheres for the treatment of glaucoma. J Control Release 2016; 228: 48-57. [PMID: 26930266 DOI: 10.1016/j.jconrel.2016.02.041]

[179] Ciulla T, Yeh S. Microinjection via the suprachoroidal space: a review of a novel mode of administration. Am J Manag Care 2022; 28(suppl 13): S243-52. [PMID: 36395492 DOI: 10.37765/ajmc.2022.89270]

[180] Kim YC, Edelhauser HF, Prausnitz MR. Targeted delivery of antiglaucoma drugs to the supraciliary space using microneedles. Invest Ophthalmol Vis Sci 2014; 55(11): 7387-97. [PMID: 25212782 DOI: 10.1167/iovs.14-14651]

[181] Wang H, Xu J, Xiang L. Microneedle-mediated transcutaneous immunization: potential in nucleic acid vaccination. Adv Healthc Mater 2023; 12(23): e2300339. [PMID: 37115817 DOI: 10.1002/adhm.202300339]

[182] Jiang X, Jin Y, Zeng Y, Shi P, Li W. Self-implantable core-shell microneedle patch for long-acting treatment of keratitis via programmed drug release. Small 2024; 20(29): 2310461. [DOI: 10.1002/smll.202310461]